• 1
    White HS, Woodhead JH, Franklin MR, Swinyard EA, Wolf HH. General principles: experimental selection, quantification, and evaluation of antiepileptic drugs. In: LevyRH, MattsonRH, MeldrumBS, eds. Antiepileptic drugs, Fourth Edition. New York : Raven Press, Ltd., 1995: 99110.
  • 2
    White HS. Mechanisms of antiepileptic drugs. In: PorterR, ChadwickD, eds. Epilepsies II. Boston , MA : Butterworth-Heinemann, 1997: 130.
  • 3
    White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. Discovery and preclinical development of antiepileptic drugs. In: LevyRH, MattsonRH, MeldrumB, PeruccaE, eds. Antiepileptic drugs. Philadelphia : Lippincott, 2002: 3648.
  • 4
    Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 1937;85: 5256.
  • 5
    Lennox WG. The petit mal epilepsies. Their treatment with Tridione. JAMA 1945;129: 106974.
  • 6
    Snead OC. Pharmacological models of generalized absence seizures in rodents. J Neural Transm 1992;35: 719.
  • 7
    Marescaux C, Vergnes M. Genetic absence epilepsy in rats from Strasbourg (GAERS). Ital J Neurol Sci 1995;16: 1138.
  • 8
    Hosford DA, Clark S, Cao Z, et al. The role of GABAB receptor activation in absence seizures of lethargic (lh/lh) mice. Science 1992;257: 398401.
  • 9
    Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38: 40814.
  • 10
    Loscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and models with spontaneous recurrent seizures. Epilepsy Res 2002;50: 10523.
  • 11
    Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47: 21727.
  • 12
    Smyth MD, Barbaro NM, Baraban SC. Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia. Epilepsy Res 2002;50: 25164.
  • 13
    Gower AJ, Noyer M, Verloes R, Gobert J, Wulfert E. ucb LO59, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222: 193203.
  • 14
    Loscher W, Honack D. Profile of ucb-L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993;232: 14758.
  • 15
    Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995;22: 20713.
  • 16
    Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353: 191206.
  • 17
    Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284: 4749.
  • 18
    Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;25: 295330.
  • 19
    Loscher W, Honack D. Responses to NMDA receptor antagonists altered by epileptogenesis [Editorial comment]. Trends Pharmacol Sci 1991;12: 52.
  • 20
    Loscher W, Reissmuller E, Ebert U. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. Epilepsy Res 2000;40: 6377.
  • 21
    Nissinen J, Halonen T, Koivisto E, Pitkanen A. A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat. Epilepsy Res 2000;38: 177205.
  • 22
    Brown WC, Schiffman DO, Swinyard EA, Goodman LS. Comparative assay of antiepileptic drugs by ‘psychomotor’ seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 1953;107: 27383.
  • 23
    Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000;41: 2833.
  • 24
    Singh NA, Charlier C, Stauffer D, et al. A novel potsssium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998;18: 259.
  • 25
    Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998;279: 4036.
  • 26
    Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001;42: 51524.
  • 27
    Loscher W. Animal models of intractable epilepsy. Prog Neurobiol 1997;53: 23958.
  • 28
    Dalby NO, Mody I. The process of epileptogenesis: a pathophysiological approach. Curr Opin Neurol 2001;14: 18792.
  • 29
    McNamara JO. Analyses of the molecular basis of kindling development. Psychiatry Clin Neurosci 1995;49: S1758.
  • 30
    Pitkanen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. The Lancet Neurol 2002;1: 17381.
  • 31
    Lado FA, Sankar R, Lowenstein D, Moshe SL. Age-dependent consequences of seizures: relationship to seizure frequency, brain damage, and circuitry reorganization. Ment Retard Dev Disabil Res Rev 2000;6: 24252.
  • 32
    Sankar R, Shin D, Mazarati AM, et al. Epileptogenesis after status epilepticus reflects age- and model-dependent plasticity. Ann Neurol 2000;48: 5809.
  • 33
    Andre V, Ferrandon A, Marescaux C, Nehlig A. Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 2001;47: 99117.
  • 34
    Andre V, Ferrandon A, Marescaux C, Nehlig A. The lesional and epileptogenic consequences of lithium-pilocarpine-induced status epilepticus are affected by previous exposure to isolated seizures: effects of amygdala kindling and maximal electroshocks. Neuroscience 2000;99: 46981.
  • 35
    Echlin F, Battista J. Epileptiform seizures from chronic isolated cortex. Arch Neurol 1963;9: 15470.
  • 36
    Sharpless S, Halpern L. The electrical excitability of chronically isolated cortex studied by means of chronically implanted electrodes. Electroencephalogr Clin Neurophysiol 1962;14: 24455.
  • 37
    Prince DA, Jacobs K. Inhibitory function in two models of chronic epileptogenesis. Epilepsy Res 1998;32: 8392.
  • 38
    Bush PC, Prince DA, Miller KD. Increased pyramidal excitability and NMDA conductance can explain postraumatic epileptogenesis without disinhibition: a model. J Neurophysiol 1999;82: 174858.
  • 39
    Willmore LJ, Sypert GW, Munson JV, Hurd RW. Chronic focal epileptiform discharges induced by injection of iron into rat and cat cortex. Science 1978;200: 15013.
  • 40
    Willmore LJ, Rubin JJ. Effects of antiperoxidants on FeCl2-induced lipid-peroxidation and focal edema in rat-brain. Exp Neurol 1984;83: 6270.
  • 41
    Lowenstein DH, Thomas MJ, Smith DH, McIntosh TK. Selective vulnerability of dentate hilar neurons following traumatic brain injury: a potential mechanistic link between head trauma and disorders of the hippocampus. J Neurosci 1992;12: 484653.
  • 42
    Laurer HL, McIntosh TK. Experimental models of brain trauma. Curr Opin Neurol 1999;12: 71521.
  • 43
    Golarai G, Greenwood AC, Feeney DM, Connor JA. Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury. J Neurosci 2001;21: 852337.
  • 44
    Jensen FE, Baram TZ. Developmental seizures induced by common early-life insults: short- and long-term effects on seizure susceptibility. Ment Retard Dev Disabil Res Rev 2000;6: 2537.
  • 45
    Jensen FE, Blume H, Alvarado S, Firkusny I, Geary C. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia 1995;36: 96672.
  • 46
    Baram TZ, Gerth A, Schlutz L. Febrile seizures: an appropriate-aged model suitable for long-term studies. Dev Brain Res 1997;98: 26570.
  • 47
    White HS. Animal models of epileptogenesis. Neurology 2002;59(suppl 5):S714.
  • 48
    Loscher W. Current status and future directions in the pharmacotherapy of epilepsy. TIPS 2002;23: 1138.